O-(2-(<sup>18</sup>F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma

Mihovilovic, Milena I; Kertels, Olivia; Hänscheid, Heribert; Löhr, Mario; Monoranu, Camelia‐Maria; Kleinlein, Irene; Samnick, Samuel; Keßler, Almuth F.; Linsenmann, Thomas; Ernestus, Ralf‐Ingo; Buck, Andreas K.; Lapa, Constantin

doi:10.1136/jnnp-2017-317155

Cited by 32 publications

(33 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For the differentiation of treatment-related changes from tumor relapse, amino acid PET also provides valuable diagnostic information. Using [ 18 F]FET or [ 18 F]FDOPA, especially the differentiation of radiation injury from tumor relapse in glioma patients, as well as in patients with brain metastases, can be obtained with a relatively high diagnostic accuracy between 80-90% ( Figure 2) [11,26,[67][68][69][70][71][72][73][74][75][76][77][78][79][80]. Importantly, in glioma patients, parameters derived from dynamic [ 18 F]FET PET acquisition may further increase the diagnostic accuracy [67,[74][75][76]78].…”

Section: Value Of Amino Acid Pet Tracers For Brain Tumor Patientsmentioning

confidence: 99%

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

et al. 2020

View full text Add to dashboard Cite

The number of positron-emission tomography (PET) tracers used to evaluate patients with brain tumors has increased substantially over the last years. For the management of patients with brain tumors, the most important indications are the delineation of tumor extent (e.g., for planning of resection or radiotherapy), the assessment of treatment response to systemic treatment options such as alkylating chemotherapy, and the differentiation of treatment-related changes (e.g., pseudoprogression or radiation necrosis) from tumor progression. Furthermore, newer PET imaging approaches aim to address the need for noninvasive assessment of tumoral immune cell infiltration and response to immunotherapies (e.g., T-cell imaging). This review summarizes the clinical value of the landscape of tracers that have been used in recent years for the above-mentioned indications and also provides an overview of promising newer tracers for this group of patients.

show abstract

Section: Value Of Amino Acid Pet Tracers For Brain Tumor Patientsmentioning

confidence: 99%

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

et al. 2020

View full text Add to dashboard Cite

show abstract

“…All patients were referred to 18 F-FET PET/CT because of MRI-based suspicion of recurrence/disease progression, as determined by the Response Assessment in Neuro-Oncology (RANO) working group criteria. 14 Patients were identified consecutively and selected according to the initial scan date, which ranged from April 2010 to August 2016. The interval between cessation of radiation therapy and subsequent PET imaging was more than 12 weeks in all cases.…”

Section: Subjectsmentioning

confidence: 99%

“…Tumor-to-brain ratios were determined according to 4 previously described 13,14,21,22 and additionally proposed semiquantitative analysis methods. Irrespective of the approach, the transaxial slice with the highest amino acid uptake was chosen for further analysis.…”

Section: Image Analysismentioning

confidence: 99%

“…13 2) Rapp et al 22 used an approach similar to (1), with the only difference of SUV max being the voxel with the highest amino acid uptake. 22 3) Mihovilovic et al 14 determined SUV max as the voxel with the maximum tracer uptake and SUV 10mm as the SUV mean in an ROI with 10-mm diameter centered on this voxel. For derivation of TBR max and TBR 10mm , a second region with 50-mm diameter including white and gray matter was selected in an area of normal-appearing brain tissue on the contralateral hemisphere of the same slice.…”

Section: Image Analysismentioning

confidence: 99%

“…P ET using O-(2-[ 18 F]fluoroethyl)-L-tyrosine ( 18 F-FET) as a marker of amino acid transport is an established tool in brain tumor imaging, including grading, [1][2][3] delineation of tumor extent, 4 biopsy guidance, 5,6 prognostication, [7][8][9] treatment monitoring, [10][11][12] and differentiation of nonspecific posttherapeutic changes from tumor recurrence. [13][14][15] In daily routine, differentiation of viable tumor from treatmentrelated changes is predominantly established by determination of tracer uptake of both the tumor and normal brain tissue and subsequent calculation of tumor-to-brain ratios (TBRs). However, various approaches for deriving the respective values have been published in the literature, hampering comparability of data between different studies and sites.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical utility of different approaches for detection of late pseudoprogression in glioblastoma with O-(2-[18F]fluoroethyl)-L-tyrosine PET

Kertels

Mihovilovic

Linsenmann

et al. 2019

57. Jahrestagung Der Deutschen Gesellschaft Für Nuklearmedizin

View full text Add to dashboard Cite

Purpose: PET/CT using O-(2-[ 18 F]fluoroethyl)-L-tyrosine (18 F-FET) has proven valuable in differentiating tumor recurrence and progression from therapy-induced changes. This study aimed to investigate the diagnostic performance of several analytic approaches in the setting of suspected late pseudoprogression (PsP) in glioblastoma multiforme (GBM). Methods: Retrospective analysis of tumor recurrence was performed in 36 patients with histopathologically confirmed GBM and suspicion of recurrence/disease progression more than 12 weeks from cessation of irradiation based on MRI and Response Assessment in Neuro-Oncology working group criteria. For differentiation of late PsP from true tumor recurrence, images were analyzed semiquantitatively employing tumor-to-brain ratios using 5 different approaches for tumor and normal brain reference region definition, respectively. Histopathology and/or clinical and imaging follow-up served as reference. Respective areas under the receiver operating characteristic curve were compared. Results: 18 F-FET PETwas able to reliably differentiate PsP from true tumor progression with areas under the receiver operating characteristic curve ranging from 0.80 to 0.88 (all P < 0.01). Irrespective of the approach chosen, the classification differences between the applied methods were not significant (all P > 0.05), albeit approaches focusing on voxels with the highest uptake tended to perform superior. Conclusions: Irrespective of the analytical approach, 18 F-FET PET is a robust tool for detection of late PsP with only minor differences between different analytical approaches. However, methodological standardization and harmonization are needed to ensure comparability between different centers.

show abstract

FET and FDOPA PET Imaging in Glioma

et al. 2019

View full text Add to dashboard Cite

O-(2-(¹⁸F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma

Cited by 32 publications

References 6 publications

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

Clinical utility of different approaches for detection of late pseudoprogression in glioblastoma with O-(2-[18F]fluoroethyl)-L-tyrosine PET

FET and FDOPA PET Imaging in Glioma

Contact Info

Product

Resources

About

O-(2-(18F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma

Cited by 32 publications

References 6 publications

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

Current Landscape and Emerging Fields of PET Imaging in Patients with Brain Tumors

Clinical utility of different approaches for detection of late pseudoprogression in glioblastoma with O-(2-[18F]fluoroethyl)-L-tyrosine PET

FET and FDOPA PET Imaging in Glioma

Contact Info

Product

Resources

About

O-(2-(¹⁸F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma